Abstract
Protein tyrosine kinases catalyze the transfer of phosphoryl groups from ATP to amino acids on proteins and play a fundamental role in signal transduction pathways in mammalian cells. In particular, Src and Src-family are non-receptor tyrosine kinases that regulate cell growth, differentiation, migration, adhesion and apoptosis. Src-family members share common features, with well defined domains. The activation of these enzymes in response to a variety of stimuli leads from a close and inactive conformation to an open and active one, through a balance of phosphorylation and dephosphorylation of the enzyme structure, characterized in different cases by Xray crystallography. Overexpression, deregulation or mutations of these enzymes have been observed and studied in many diseases, first of all in many human malignancies, such as colon, breast, pancreatic and other cancers. Src-family is also involved in other pathologic situations, such as osteoporosis, cardiovascular diseases, immune system disorders, and, recently, it has been also demonstrated the involvement of Src in prion diseases.Therefore, Src-family is an attractive and fundamental target for the design of new therapeutic agents against different pathologies, in particular cancer and bone diseases. Currently, there is no approved drug acting as Src kinase inhibitor, but new molecules, very potent and selective toward this family of kinases and also in vivo, are continuously synthesized, as demonstrated by the high number of publications and patents in this field. Here, we report several examples of Src kinase domain inhibitors, focusing our attention on chemical structures, structure-activity relationships and mechanism of action.
Keywords: Tyrosine kinases, Src, Abl, inhibitors, cancer
Anti-Cancer Agents in Medicinal Chemistry
Title: Synthetic Src-Kinase Domain Inhibitors and Their Structural Requirements
Volume: 7 Issue: 6
Author(s): Silvia Schenone, Fabrizio Manetti and Maurizio Botta
Affiliation:
Keywords: Tyrosine kinases, Src, Abl, inhibitors, cancer
Abstract: Protein tyrosine kinases catalyze the transfer of phosphoryl groups from ATP to amino acids on proteins and play a fundamental role in signal transduction pathways in mammalian cells. In particular, Src and Src-family are non-receptor tyrosine kinases that regulate cell growth, differentiation, migration, adhesion and apoptosis. Src-family members share common features, with well defined domains. The activation of these enzymes in response to a variety of stimuli leads from a close and inactive conformation to an open and active one, through a balance of phosphorylation and dephosphorylation of the enzyme structure, characterized in different cases by Xray crystallography. Overexpression, deregulation or mutations of these enzymes have been observed and studied in many diseases, first of all in many human malignancies, such as colon, breast, pancreatic and other cancers. Src-family is also involved in other pathologic situations, such as osteoporosis, cardiovascular diseases, immune system disorders, and, recently, it has been also demonstrated the involvement of Src in prion diseases.Therefore, Src-family is an attractive and fundamental target for the design of new therapeutic agents against different pathologies, in particular cancer and bone diseases. Currently, there is no approved drug acting as Src kinase inhibitor, but new molecules, very potent and selective toward this family of kinases and also in vivo, are continuously synthesized, as demonstrated by the high number of publications and patents in this field. Here, we report several examples of Src kinase domain inhibitors, focusing our attention on chemical structures, structure-activity relationships and mechanism of action.
Export Options
About this article
Cite this article as:
Schenone Silvia, Manetti Fabrizio and Botta Maurizio, Synthetic Src-Kinase Domain Inhibitors and Their Structural Requirements, Anti-Cancer Agents in Medicinal Chemistry 2007; 7 (6) . https://dx.doi.org/10.2174/187152007784111269
DOI https://dx.doi.org/10.2174/187152007784111269 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Single-cell Sequencing in the Field of Stem Cells
Current Genomics Tachykinins and the Cardiovascular System
Current Drug Targets Local Gene Delivery for Cancer Therapy
Current Gene Therapy Advances in Chemotherapy and Targeted Systemic Therapies for Urothelial Cancer
Current Drug Therapy Synergistic Approaches to Clinical Oncology Biomarker Discovery
Current Topics in Medicinal Chemistry Radioimmunotherapy of Metastatic Prostate Cancer with <sup>177</sup>Lu-DOTAhuJ591 Anti Prostate Specific Membrane Antigen Specific Monoclonal Antibody
Current Radiopharmaceuticals The Functional Role of Oncogenic LncRNA BCAR4 for Cancer Outcome
Current Pharmaceutical Design Dicoumarol: A Drug which Hits at Least Two Very Different Targets in Vitamin K Metabolism
Current Drug Targets (Section A: Molecular, Structural, and Cellular Biology of Drug Transporters) Mammalian Nucleoside Transporters
Current Drug Metabolism Inflammation and Cancer: When NF-κB Amalgamates the Perilous Partnership
Current Cancer Drug Targets Impact of p53 arg72pro SNP on Breast Cancer Risk in North Indian Population
Current Genomics Impact of Drug Metabolism/Pharmacokinetics and their Relevance Upon Taxus-based Drug Development
Current Drug Metabolism Nucleic Acid Carrier Systems Based on Polyethylenimine Conjugates for the Treatment of Metastatic Tumors
Current Medicinal Chemistry A Review on Epigenetic Effects of Environmental Factors Causing and Inhibiting Cancer
Current Molecular Medicine Ghrelin: A Gastric Peptide that Regulates Hypothalamic Control of Feeding
Current Medicinal Chemistry - Central Nervous System Agents Mechanisms to Inhibit Matrix Metalloproteinase Activity: Where are we in the Development of Clinically Relevant Inhibitors?
Recent Patents on Anti-Cancer Drug Discovery MicroRNAs (miRNAs) as Biomarker(s) for Prognosis and Diagnosis of Gastrointestinal (GI) Cancers
Current Pharmaceutical Design Current Scenario of 1,4-Diazepines as Potent Biomolecules-A Mini Review
Mini-Reviews in Medicinal Chemistry Reduced Nicotinamide Adenine Dinucleotide (NADH) Fluorescence for the Detection of Cell Death
Anti-Cancer Agents in Medicinal Chemistry Curcumin and its Formulations: Potential Anti-Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry